Date:
02/05/2023
Pivotal U.S. phase II/III clinical trial has started recruiting patients AntiBKV antibody therapeutic has potential to be first- and best-in-class treatment; scheduled to be launched in 2025 Schlieren / Zurich,…
Date:
24/01/2023
Clinical trial met primary endpoint of safety and tolerability IND submission planned in Q1 2023 to initiate U.S. multicenter study Schlieren / Zurich, Switzerland – January 24, 2023 – Memo…
